Functional Capacity Assessment for Parkinson’s Disease and Huntington’s Disease

Parkinson’s disease and Huntington’s disease are both progressive neurological conditions that affect movement, cognition and daily functioning. Both are included in NDIS Condition List B, meaning that a diagnosis alone does not establish NDIS eligibility — functional evidence is required. Both conditions raise specific and clinically important challenges for NDIS planning: Parkinson’s disease because of its fluctuating medication response and variable daily functioning, and Huntington’s disease because of its genetic nature, its combined motor, cognitive and psychiatric presentation and its inevitable progression. This article explains each condition in clinical detail and outlines what a Functional Capacity Assessment must document for each.
Part One: Parkinson’s Disease
What is Parkinson’s disease?
Parkinson’s disease is a progressive neurodegenerative condition caused by the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. Dopamine is a neurotransmitter that plays a central role in coordinating smooth, controlled movement. As dopamine levels fall, the motor control system becomes increasingly impaired, producing the characteristic movement difficulties of the condition. Parkinson’s disease affects approximately 100,000 Australians and is the second most common neurodegenerative condition after Alzheimer’s disease. It typically affects people over the age of 60, though approximately 20 per cent of people with Parkinson’s disease develop symptoms before the age of 65 — these individuals are eligible for NDIS support.
Parkinson’s disease is a progressive condition, but the rate of progression varies considerably between individuals. It is not a fatal condition in itself, though complications of advancing disease including falls, aspiration pneumonia and immobility significantly affect life expectancy in later stages. With appropriate treatment and support, many people with Parkinson’s disease maintain meaningful independence and quality of life for many years following diagnosis.
The four cardinal motor features of Parkinson’s disease
- Tremor: an involuntary, rhythmic shaking that is most prominent at rest and that typically begins in one hand. Rest tremor is the most recognisable feature of Parkinson’s disease but is not present in all people with the condition. Tremor affects fine motor tasks including writing, using cutlery, managing buttons and using technology.
- Rigidity: increased muscle stiffness and resistance to passive movement, which affects the full range of movement and contributes to pain, postural changes and difficulty with transfers and self-care. Rigidity may present as a cogwheel pattern (intermittent resistance) or as lead-pipe rigidity (uniform resistance throughout the movement range).
- Bradykinesia: slowness of movement and reduction in the amplitude of movement, which is the most disabling motor feature for many people with Parkinson’s disease. Bradykinesia affects all physical tasks, making them take significantly longer than before the illness. Tasks that previously took minutes may take much longer, and the person may be unable to initiate movement despite intending to do so.
- Postural instability: impaired balance and postural reflexes that increase the risk of falls and that typically emerge in the middle stages of the disease. Postural instability does not respond as well to levodopa as the other motor features and is a major source of disability and falls-related injury in the later stages of the condition.
Freezing of gait
Freezing of gait is an episodic inability to initiate or continue walking despite the intention to do so. The person’s feet appear to be glued to the floor. It typically occurs when initiating movement from a standing position, when turning, when approaching narrow spaces such as doorways and when under time pressure or stress. Freezing of gait is a significant falls risk and a major source of community access limitation. It can be partially managed through environmental cueing strategies but remains one of the most challenging and distressing features of Parkinson’s disease for daily functioning.
The ON and OFF phenomenon: the most important feature for NDIS planning
Most people with Parkinson’s disease who are treated with levodopa (the primary medication for managing motor symptoms) experience fluctuations in their motor function that cycle between periods of better symptom control and periods of significantly reduced symptom control. These are referred to as ON periods and OFF periods.
During an ON period, the medication is working effectively. The person may have substantially better mobility, reduced tremor, improved ability to initiate movement and greater capacity to perform daily living tasks independently or with less assistance. During an OFF period, the medication effect has worn off before the next dose takes effect, or the medication has failed to absorb adequately. During an OFF period, the person may experience severe bradykinesia, rigidity and freezing that can make independent daily activities completely impossible. They may be unable to rise from a chair, turn in bed, walk to the toilet or manage basic self-care without full physical assistance.
Why the ON/OFF phenomenon is critical for NDIS documentation
A Functional Capacity Assessment completed during an ON period will significantly overestimate the person’s functional capacity and underestimate their support needs.
An NDIS plan based only on ON period function will be completely inadequate during OFF periods, which may represent a substantial proportion of the person’s day.
The Functional Capacity Assessment must document functioning across both motor states, with specific documentation of what the person can manage independently during an ON period, what they can manage with assistance during an ON period and what they require during an OFF period.
Where possible, the assessment should be conducted across different parts of the day when different medication states are likely to be present.
Collateral history from carers and family members who see the person across the full daily cycle is essential.
Non-motor symptoms of Parkinson’s disease
Non-motor symptoms of Parkinson’s disease are often as disabling as the motor features and are consistently underrepresented in NDIS assessments. They include the following.
- Cognitive impairment and dementia: executive functioning difficulties are common from early in the disease course, progressing in later stages to Parkinson’s disease dementia in a proportion of people. Memory, attention and processing speed are all affected.
- Depression and anxiety: occur in the majority of people with Parkinson’s disease and are directly related to the neurobiological changes of the condition, not only a psychological response to diagnosis. Both significantly affect daily functioning and motivation.
- Sleep disturbance: including REM sleep behaviour disorder (acting out dreams during sleep, which can be a presenting symptom years before motor symptoms emerge), excessive daytime sleepiness, insomnia and restless legs. Sleep disruption compounds fatigue and cognitive impairment.
- Autonomic dysfunction: blood pressure instability including orthostatic hypotension (dizziness and falls on standing), bowel and bladder dysfunction and difficulty with temperature regulation.
- Pain: neuropathic pain, musculoskeletal pain from rigidity and abnormal posture and the pain associated with dystonia (abnormal sustained muscle contractions) are common and directly affect daily functioning and sleep.
- Swallowing and communication: dysphagia and speech changes (hypophonia — reduced voice volume; dysarthria — unclear articulation) affect communication, eating safety and the ability to engage with services and systems.
Part Two: Huntington’s Disease
What is Huntington’s disease?
Huntington’s disease is an inherited neurodegenerative condition caused by a genetic mutation on chromosome 4. It is autosomal dominant, meaning that a person who carries the mutation has a 50 per cent chance of passing it to each child. A child who inherits the mutation will develop the condition, though the age of symptom onset is variable. Huntington’s disease is rare, affecting approximately 2,000 to 3,000 Australians with manifest disease, with a further number who are gene positive but have not yet developed symptoms.
Huntington’s disease causes progressive degeneration of specific brain regions, particularly the striatum and caudate nucleus, which are involved in movement control, cognition and behaviour. The condition is invariably fatal, with average survival of 10 to 25 years after symptom onset. There is currently no disease-modifying treatment that slows the progression of Huntington’s disease. Management is focused on symptomatic treatment and maximising quality of life and function across the disease course.
Because of the genetic nature of Huntington’s disease, family members of a person with the condition may know they are at risk and may choose to undergo genetic testing to determine whether they carry the mutation. People who test positive but have not yet developed symptoms are in the pre-manifest phase. This phase has specific NDIS planning implications that are addressed below.
The three core symptom domains of Huntington’s disease
| Domain | Features | Functional impact |
| Motor symptoms | Chorea: involuntary, irregular, unpredictable movements affecting the limbs, trunk, face and sometimes the whole body. Dystonia: sustained abnormal muscle contractions and postures. Bradykinesia and rigidity in later stages. Gait disturbance and falls risk. Dysphagia and dysarthria. | Chorea directly affects all fine motor tasks, balance, gait and safe community access. Dysphagia creates aspiration risk and requires dietary modification. Dysarthria affects communication. Falls risk increases significantly with disease progression. |
| Cognitive symptoms | Executive functioning impairment from early in the disease course: difficulty with planning, organising, initiating tasks, problem solving and cognitive flexibility. Memory impairment. Slowed processing speed. Progressive cognitive decline to dementia in later stages. | Executive dysfunction directly affects independent daily living from early in the disease course. Cognitive decline in later stages requires increasing support across all daily living domains. Impaired insight and judgment affect safety. |
| Psychiatric symptoms | Depression is the most common psychiatric symptom and may precede motor symptoms by years. Irritability and mood lability. Anxiety. Obsessive-compulsive behaviours. Apathy. Psychosis in a proportion of people. Personality changes. | Depression, apathy and irritability affect motivation, engagement with support and relationships. Psychiatric symptoms may be more disabling than motor symptoms in the early and middle stages of the disease. Behavioural changes affect housing stability and relationships. |
The pre-manifest phase and its NDIS implications
Individuals who have tested positive for the Huntington’s disease mutation but who have not yet developed clinical symptoms are in the pre-manifest phase. Research has shown that subtle cognitive and psychiatric changes, particularly in executive functioning and emotional regulation, may be present years before the formal symptom threshold is crossed. These pre-manifest changes can begin to affect daily functioning in ways that are clinically meaningful even when a formal diagnosis of manifest Huntington’s disease has not yet been made.
For NDIS purposes, a person in the pre-manifest phase does not yet have a diagnosis of manifest Huntington’s disease and is unlikely to meet the NDIS disability requirements at this stage unless other conditions are also present. However, planning ahead and accessing appropriate supports through other avenues, including health and community services, is clinically important given the inevitable trajectory of the condition.
Huntington’s disease and NDIS eligibility
Huntington’s disease is included in NDIS Condition List B. The diagnosis alone does not establish eligibility — functional evidence of substantially reduced functional capacity is required. Given the progressive nature of the condition, the timing of the NDIS application and the Functional Capacity Assessment is important. A person who applies while still in the early stages of the disease may find it difficult to demonstrate substantially reduced functional capacity if support needs are not yet significant. However, waiting until needs are severe may result in a delayed access to supports that would have been beneficial earlier.
Comparing Parkinson’s disease and Huntington’s disease
| Feature | Parkinson’s disease | Huntington’s disease |
| Cause | Loss of dopamine-producing neurons in the substantia nigra. Primarily sporadic (no family history) in most cases. | Autosomal dominant genetic mutation. Each child of a person with HD has 50% chance of inheriting it. |
| Onset age | Typically over 60. Younger onset (under 65) in 20% of cases. | Typically 30 to 50 years. Juvenile onset is rare but occurs. |
| Primary motor feature | Tremor (often asymmetric), rigidity, bradykinesia, postural instability. | Chorea (involuntary, irregular movements) — very different from Parkinson’s tremor. |
| Medication response | Good response to levodopa especially early. Creates ON/OFF fluctuations. | No disease-modifying treatment. Symptomatic treatment for chorea, depression and behaviour. |
| Cognitive impairment | Executive dysfunction common. Dementia in later stages. | Executive dysfunction from early stages. Progressive to dementia. |
| Psychiatric features | Depression, anxiety common. Psychosis less common. | Depression, irritability, apathy, obsessive-compulsive features, psychosis all common. |
| Course | Progressive but variable rate. Relatively longer survival. | Invariably fatal. Average 10 to 25 years after symptom onset. |
| NDIS eligibility | Condition List B. Functional evidence required. Under 65 at application. | Condition List B. Functional evidence required. |
NDIS planning challenges shared by both conditions
Despite their clinical differences, Parkinson’s disease and Huntington’s disease share several NDIS planning challenges that the Functional Capacity Assessment must specifically address.
Functional fluctuation
In Parkinson’s disease, fluctuation is driven by medication response (ON and OFF periods). In Huntington’s disease, fluctuation is driven by fatigue, emotional state and the episodic nature of some symptoms. In both conditions, the NDIS plan must be based on the full range of functional capacity — not only on the person’s best periods — and must fund support that is adequate for the most demanding phases of the daily cycle.
Progressive deterioration
Both conditions are progressive. The Functional Capacity Assessment must not only document current functional capacity but also provide clinical reasoning about the likely trajectory of the condition and how support needs are likely to change. NDIS plans for people with progressive neurological conditions should be designed with anticipated future needs in mind and should include clear triggers for plan review as the condition advances.
Non-motor symptoms frequently underrepresented
The non-motor symptoms of both conditions — cognitive impairment, depression, anxiety, behavioural changes, sleep disturbance and autonomic dysfunction — are frequently not captured in NDIS assessments that focus primarily on physical function. Yet in both conditions, non-motor symptoms often produce greater functional limitation in daily life than the motor features. The Functional Capacity Assessment must specifically assess and document non-motor symptoms and their functional impact across each NDIS domain.
What a Functional Capacity Assessment covers
- For Parkinson’s disease: assessment of motor function during both ON and OFF medication states, with specific documentation of what the person can manage independently, what requires assistance and what requires full physical support in each state
- For Parkinson’s disease: assessment of freezing of gait, its frequency and its functional and safety implications
- For Huntington’s disease: assessment of chorea and its functional impact on fine motor tasks, balance, gait, eating and self-care
- Assessment of swallowing and communication and the support required for safe eating and effective daily communication in both conditions
- Assessment of cognitive functioning in the context of actual daily tasks, including executive functioning, memory and the capacity for independent daily life management
- Assessment of psychiatric and behavioural symptoms and their functional impact, including depression, apathy, irritability and, where relevant, psychosis
- Assessment of falls risk and the supervision and environmental modifications required for safe daily living
- Assessment of the level and type of personal care assistance required, including transfers, mobility assistance, self-care and medication management
- Documentation of functional capacity across the full daily cycle, including across different medication states in Parkinson’s disease
- Prospective clinical reasoning regarding the likely trajectory of the condition and future support needs
- Recommendations for assistive technology and home modifications appropriate to current and anticipated future functional needs
The 2026 NDIS context
The Securing the NDIS for Future Generations Bill 2026, introduced to Parliament on 14 May 2026, strengthens the requirement that NDIS supports must have a direct causal connection to the eligible impairment. For people with Parkinson’s disease and Huntington’s disease, this means the Functional Capacity Assessment must clearly document how the specific features of each condition — the ON/OFF fluctuations of Parkinson’s disease, the chorea and cognitive changes of Huntington’s disease, and the non-motor symptoms of both — cause the functional impairments documented and justify the support recommendations made. Parkinson’s Australia has noted that a well-designed functional assessment framework has the potential to better capture the real-world impact of Parkinson’s disease than a diagnosis-based approach, though the detail of implementation will be critical.
Who can refer?
Referrals are accepted from participants and families, support coordinators, neurologists, Parkinson’s nurses, GPs and legal representatives involved in NDIS appeals. Sina OT has completed Functional Capacity Assessments for individuals with progressive neurological conditions across Adelaide, Melbourne and Sydney. All assessments are completed in person in the participant’s home and community environment.
Disclaimer
The information in this article is provided for general informational purposes only. NDIS rules, legislation, policy and clinical frameworks are subject to change. Sina OT does not accept responsibility for decisions made in reliance on information contained in this article. Participants, families, support coordinators and other professionals should always refer directly to the NDIS website at ndis.gov.au and consult with qualified professionals regarding their individual circumstances.
Refer to Sina OT
Sina OT is an independent Occupational Therapy practice providing Functional Capacity Assessments across Adelaide, Melbourne and Sydney.
Sina OT has completed Functional Capacity Assessments for individuals with progressive neurological conditions including Parkinson’s disease and Huntington’s disease. All assessments are completed in person in the participant’s home and community environment by a registered Occupational Therapist.
Services are available in English and Farsi (Persian).
Phone: 0467 712 199 | Email: sina@sinaot.com.au
Related Insight Articles
NDIS Funding Changes 2026: The High Support Needs Safeguard Pathway Explained
From 1 October 2026 the Australian Government is resetting funding for two categories of NDIS support. This will affect all participants who receive funding for these supports. A separate safeguard pathway has been created for participants with the highest and most complex support needs, to ensure they continue to have enough funding to maintain 24-hour disability support safely. This article explains exactly who qualifies, how the pathway works and where a Functional Capacity Assessment strengthens an application.
How to Refer a Client for an NDIS FCA
If you or someone you support has been told they need a Functional Capacity Assessment, it is completely normal to feel unsure about what that actually means. This article explains what an NDIS Functional Capacity Assessment is
What is an NDIS Functional Capacity Assessment?
If you or someone you support has been told they need a Functional Capacity Assessment, it is completely normal to feel unsure about what that actually means. This article explains what an NDIS Functional Capacity Assessment is



